Trouble with images? View as a Web page.

Polsinelli - FDA Regulatory
         
 

December 2013

 

Draft Guidance: Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

 
 
             
 

For more information about this e-Alert, please contact:

 

Melissa Gilmore

Author

202.626.8373

mgilmore@polsinelli.com

 

FDA Regulatory Practice Leaders:

 

Kevin R. Sweeney

Practice Area Chair

816.572.4638

ksweeney@polsinelli.com

 

Geoffrey D. Fasel

Practice Area Vice Chair

816.360.4223

gfasel@polsinelli.com

 
 

To learn more about our FDA Regulatory practice, or to contact one of our FDA Regulatory attorneys, click here.

 

View Polsinelli documents on JD Supra  
LinkedIn Twitter Facebook Inside Law Podcast Connect with us on LinkedIn. Connection with us on Twitter. Connect with us on Facebook.

 

   

Following enactment of the Drug Quality and Security Act last month, FDA has quickly issued a new guidance for compounding pharmacies that choose to not register as "outsourcing facilities" and subject themselves to federal oversight. The Draft Guidance lists 10 conditions that pharmacies must follow in order to remain regulated by state Boards of Pharmacy under 21 USC 353A. Remaining under state jurisdiction exempts these "traditional" compounding pharmacies from the requirements of the U.S. Food, Drug, & Cosmetic Act that are generally applicable to drug manufacturers, such as GMP, labeling, and prior new drug approval.

Under the Draft Guidance, in order for FDA not to consider the pharmacy and compounded product subject to federal FDA regulation, the pharmacy must compound:

  1. based on a prescription for an individual patient;

  2. in a pharmacy in limited quantities if there is a history of prescriptions from a licensed practitioner;

  3. in compliance with USP;

  4. compounded using bulk substances from a FDA registered facility;

  5. using substances accompanied by valid certificates of analysis;

  6. in compliance with an USP or NF monograph, if it is not compounded from a bulk substance;

  7. not on the list of products removed from the market;

  8. not "essentially copies of commercially available drug products;"

  9. not a product identified by the FDA as presenting demonstrable difficulties for compounding; and

  10. subject to inspection.

The 5% Rule and Inspections

The Act returns the state of the law to 2002 by imposing the limitations for "inordinate amounts" and "5%" under 353a(b)(3)(B)(i-ii). Under 353a(b)(1)(D) "a drug product may be compounded" if the pharmacist (or physician) "does not compound regularly or in inordinate amounts...any drug products that are essentially copies of commercially available drug products." The phrase "inordinate amounts" is to be defined by the FDA. The 5% limitation provides that a pharmacy may not compound a product unless:

  1. The state where the drug is compounded has a memorandum of understanding (MOU) with the FDA for state investigations of complaints relating to "compounded drug products" distributed out of state; or

  2. The total compounded products distributed out of state do not exceed 5% of the total prescription orders.

FDA states that it "does not intend to enforce the 5% limitation until 90 days after FDA has finalized an MOU and made it available to the State... ."

For More Information

For more information about the contents of this eAlert, please contact the author:

 
             
             

             
 

Chattanooga  Chicago  Dallas  Denver  Edwardsville  Jefferson City  Kansas City  Los Angeles  New York  Overland Park
Phoenix  St. Joseph  St. Louis  Springfield  Topeka  Washington, D.C.  Wilmington  
www.polsinelli.com

 
             
 
 

ABOUT POLSINELLI

real challenges. real answers.SM  
Serving corporations, institutions, entrepreneurs, and individuals, our attorneys build enduring relationships by providing legal counsel informed by business insight to help clients achieve their objectives. This commitment to understanding our clients' businesses has helped us become the fastest growing law firm in the U.S. for the past five years, according to the leading legal business and law firm publication,
The American Lawyer. Our more than 680 attorneys in 17 cities work with clients nationally to address the challenges of their roles in health care, financial services, real estate, life sciences and technology, energy and business litigation. The firm can be found online at www.polsinelli.com. Polsinelli PC. In California, Polsinelli LLP.

 
 
             
 

To update your email preferences, please contact Kim Auther at KAuther@polsinelli.com. To opt out of these communications, click the unsubscribe link below.

Polsinelli provides this material for informational purposes only. The material provided herein is general and is not intended to be legal advice. The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Copyright © 2013 Polsinelli PC.

 
             
Connect with us on LinkedIn. Connection with us on Twitter. Connect with us on Facebook.